Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687901 | 0.83 | TSHR (0.40) | ALDH1A1TDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2723135 | 0.83 | TSHR (0.36) | TSHRLMNA | |
| SCHEMBL4245358 | 0.80 | MAPK1 (0.46) | NPC1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL9389406 | 0.78 | KEAP1 (0.41) | ALDH1A1TDP1KEAP1RAB9ANPC1 | |
| SCHEMBL903515 | 0.78 | S1PR1 (0.61) | ALDH1A1LMNASLC6A3 | |
| SCHEMBL19326619 | 0.77 | ALDH1A1 (0.41) | ALDH1A1TDP1KEAP1RAB9ANPC1 | |
| Biphenyl SCHEMBL27676192 | 0.77 | CRHBP (0.44) | ALDH1A1TDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8351999 | 0.76 | LMNA (0.50) | ALDH1A1TDP1TSHRLMNA | |
| SCHEMBL27794151 | 0.74 | LMNA (0.39) | ALDH1A1TDP1TSHRCPA1LMNA | |
| Aniline SCHEMBL27543715 | 0.74 | TSHR (0.42) | ALDH1A1TDP1SMN1; SMN2TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632889-B1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD (IL) | 2018-08-29 | — | — | EP | disclosed |
| WO-2015107548-A1 | IMPROVED FINGOLIMOD PROCESS | EMCURE PHARMACEUTICALS LIMITED (IN) | 2015-07-23 | — | — | WO | disclosed |
| US-8735627-B2 | Intermediate compounds and process for the preparation of fingolimod | MAPI PHARMA LTD. (IL) | 2014-05-27 | — | — | US | disclosed |
| US-8735627-B2 | Intermediate compounds and process for the preparation of fingolimod | MAPI PHARMA LTD. (IL) | 2014-05-27 | — | — | US | disclosed |
| US-8735627-B2 | Intermediate compounds and process for the preparation of fingolimod | MAPI PHARMA LTD. (IL) | 2014-05-27 | — | — | US | disclosed |
| EP-2632889-A2 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | Mapi Pharma Limited (IL) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217899-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2013-08-22 | — | — | US | disclosed |
| US-20130217899-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2013-08-22 | — | — | US | disclosed |
| US-20130217899-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2013-08-22 | — | — | US | disclosed |
| WO-2012056458-A2 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012056458-A2 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012041359-A1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217899-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | S1PR2, S1PR4, S1PR3 | ALDH1A1 738/4885TDP1 1466/4885KEAP1 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.